LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

Начало・Списък с акции・Bio-Techne Corp

Bio-Techne Corp

Отворен

Сектор Здравеопазване

70.88 1.82

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

69.5

Максимум

70.88

Ключови измерители
By Trading Economics
Приходи	-8.5M 41M
Продажби	-303B 306M
P/E Средно за сектора	50.64 112.16
EPS	0.49
Марж на печалбата	13.26
EBITDA	92M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+16.92 upside

Дивиденти
By Dow Jones
Следващи печалби	30.10.2024 г.
Следваща дата на дивидент	22.11.2024 г.
Следваща дата на екс-дивидент	7.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-972M 11B
Предишно отваряне	69.06
Предишно затваряне	70.88

Настроения в новините

By Acuity

77%

23%

368 / 389 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

69.93 / 71.24 Подкрепа & съпротива

Bio-Techne Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.10.2024 г., 23:02 ч. UTC

Топ новини

Australian Consumer-Confidence Recovery Still Intact Amid Building Rate-Cut Hopes

28.10.2024 г., 23:01 ч. UTC

Значими двигатели на пазара

Lithium Americas Shares Rise After News of DOE Loan

28.10.2024 г., 22:40 ч. UTC

Печалби

Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26

28.10.2024 г., 22:29 ч. UTC

Печалби

Waste Management Posts Revenue Growth on Price Increases

28.10.2024 г., 23:52 ч. UTC

Топ новини

McDonald's Finds an Unlikely Savior to Finally Fix Its McFlurry Machines -- Update

28.10.2024 г., 23:42 ч. UTC

Пазарно говорене

Lithium Spodumene Prices Have Likely Bottomed -- Market Talk

28.10.2024 г., 23:07 ч. UTC

Топ новини

McDonald's Finds an Unlikely Savior to Finally Fix Its McFlurry Machines -- WSJ

28.10.2024 г., 23:00 ч. UTC

Печалби

WuXi AppTec 3Q Rev CNY10.46B, Down 2% on Year >603259.SH

28.10.2024 г., 22:59 ч. UTC

Печалби

WuXi AppTec 3Q Net CNY2.29B , Down 17% on Year >603259.SH

28.10.2024 г., 22:15 ч. UTC

Печалби

Sandfire Resources Net Debt $345 Million at End-Sept

28.10.2024 г., 22:15 ч. UTC

Печалби

Sandfire Resources 1Q Underlying Ebitda $121 Million

28.10.2024 г., 22:15 ч. UTC

Печалби

Sandfire Resources 1Q Unaudited Sales Revenue $282 Million

28.10.2024 г., 22:14 ч. UTC

Печалби

Sandfire Resources 1Q Underlying Operating Cost of $78/Ton of Ore Processed at Matsa Operation

28.10.2024 г., 22:14 ч. UTC

Печалби

Sandfire Resources 1Q Underlying Operating Cost of $40/Ton of Ore Processed at Motheo Operation

28.10.2024 г., 22:13 ч. UTC

Печалби

Sandfire Resources Says Copper Equivalent Output at Matsa Operation Up 4% in 1Q

28.10.2024 г., 22:13 ч. UTC

Печалби

Sandfire Resources Reaffirms FY 2025 Output, Cost, Capex Guidance

28.10.2024 г., 22:12 ч. UTC

Печалби

Sandfire Resources 1Q Silver Output 1.3 Million Oz, Up 9% on Quarter

28.10.2024 г., 22:12 ч. UTC

Печалби

Sandfire Resources 1Q Lead Output 2,081 Tons, Up 9% on Quarter

28.10.2024 г., 22:12 ч. UTC

Печалби

Sandfire Resources 1Q Zinc Output 21,542 Tons, Down 1% on Quarter

28.10.2024 г., 22:11 ч. UTC

Печалби

Sandfire Resources 1Q Copper Output 27,012 Tons, Down 1% on Quarter

28.10.2024 г., 22:11 ч. UTC

Печалби

Sandfire Resources 1Q Copper Equivalent Output 38,000 Tons, Flat on Quarter

28.10.2024 г., 22:07 ч. UTC

Печалби

China Southern Airlines: Strong Travel Demand Supported Results >1055.HK

28.10.2024 г., 22:07 ч. UTC

Печалби

China Southern Airlines 9-Mos Rev CNY134.66B Vs. CNY119.49B >1055.HK

28.10.2024 г., 22:07 ч. UTC

Печалби

China Southern Airlines 9-Mos Net CNY1.97B Vs. Net CNY1.32B >1055.HK

28.10.2024 г., 22:01 ч. UTC

Печалби

CMOC Group: Higher Income From Mining and Processing Segment Supported Results >3993.HK

28.10.2024 г., 22:00 ч. UTC

Печалби

CMOC Group 3Q Rev CNY51.94B, Up 15.5% on Year >3993.HK

28.10.2024 г., 21:59 ч. UTC

Печалби

CMOC Group 3Q Net CNY2.86B , Up 64.1% on Year >3993.HK

28.10.2024 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Fomento Economico Mexicano to Sell Plastics Solutions Operations to AMMI for MXN3.17B

28.10.2024 г., 21:23 ч. UTC

Печалби

Waste Management Raises 2024 Revenue View to Up 6% >WM

28.10.2024 г., 21:21 ч. UTC

Печалби

Waste Management 3Q Adj EPS $1.96 >WM

Сравнение с други в отрасъла

Ценова промяна

Bio-Techne Corp Прогноза

Ценова цел

By TipRanks

16.92% нагоре

12-месечна прогноза

Среден 82.29 USD 16.92%

Висок 95 USD

Нисък 65 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Bio-Techne Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Bio-Techne Corp през последните 3 месеца.

Техническа оценка

By Trading Central

69.93 / 71.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

368 / 389 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bio-Techne Corp

Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.